FDA approves abbreviated new drug application for oral anxiety treatment
ANI Pharmaceuticals Inc. has received FDA approval of its abbreviated new drug application for clorazepate dipotassium tablets, according to a company press release.ANI stated that this is a generic version of Tranxene (clorazepate dipotassium, Sanofi), which is indicated for managing anxiety disorders, according to the FDA package insert.